30 Spring Mill Drive
About VenatoRx PharmaceuticalsVenatoRx Pharmaceuticals is a private pharmaceutical company dedicated to the discovery and development of novel anti-infective agents to address the threat of antibiotic resistance.
CEO: Christopher J. Burns
CDO: Luigi Xerri
COO: Ezra Felker
CFO: James G. Murphy
CMO: Tim Henkel
23 articles with VenatoRx Pharmaceuticals
VenatoRx Pharmaceuticals Names Joseph C. Larsen, Ph.D. Vice President, Strategic Portfolio Development
Dr. Larsen will help translate VenatoRx’s rich internal programs toward strategic public and private partnerships, and will help identify new growth opportunities for VenatoRx.
VenatoRx Pharmaceuticals Initiates Enrollment in Phase 3 Trial of Cefepime/VNRX-5133 in Patients with Complicated Urinary Tract Infections
VenatoRx Pharmaceuticals today announced that it has initiated enrollment in its Phase 3 trial of cefepime/VNRX-5133 in patients with complicated urinary tract infections (cUTIs).
VenatoRx Pharmaceuticals Expands Development Team as It Advances Its Antibacterial and Antiviral Portfolio
VenatoRx Pharmaceuticals today announced the addition of pharmaceutical industry veterans, Jennifer Ellis, Dr. Paul McGovern and Lauren P. Tornetta to its development team.
VenatoRx Pharmaceuticals today announced that it was named one of the “2019 Best Places to Work” in the Greater Philadelphia area by the Philadelphia Business Journal.
HHS, DoD, VenatoRx Pharmaceuticals to Co-Develop Novel Antibiotic to Treat Drug-Resistant Infections
CDC estimates that antibiotic-resistant infections affect at least two million people in the United States each year and drive $35 billion in healthcare system costs annually.
VenatoRx Pharmaceuticals Founders Named Entrepreneur Of The Year 2019 Award Winners in Greater Philadelphia
VenatoRx Pharmaceuticals today announced that its founders, Christopher J. Burns, Ph.D., Daniel C. Pevear, Ph.D., and Luigi Xerri, Ph.D., received the Entrepreneur Of The Year® 2019 Award in the Health and Life Sciences category in Greater Philadelphia.
VenatoRx Pharmaceuticals will present ten posters featuring its two development-stage products, cefepime/VNRX-5133 and ceftibuten/VNRX-7145, at ASM Microbe 2019 to be held June 20-24 in San Francisco, CA.
VenatoRx Pharmaceuticals to Present Data for its Injectable and Orally Bioavailable Beta-Lactamase Inhibitor Drug Candidates at ECCMID 2019
The 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held April 13-16, 2019 in Amsterdam, The Netherlands.
VenatoRx Pharmaceuticals today announced that Lisa Wittmer, Ph.D. has joined the Company as Chief Development Officer.
VenatoRx Pharmaceuticals to Present Orally Bioavailable Broad-Spectrum Beta-Lactamase Inhibitor for Superbugs at ACS National Meeting
VenatoRx Pharmaceuticals announced that its President and CEO, Christopher J. Burns, Ph.D., will present during the First Time Disclosure of Clinical Candidates at the American Chemical Society (ACS) National Meeting.
VenatoRx Pharmaceuticals’ Christopher J. Burns, Ph.D. Named CEO of the Year by Life Sciences Pennsylvania
Recognition honors a CEO who has demonstrated visionary leadership and active participation to advance the life sciences and biotech industry
VenatoRx Pharmaceuticals Awarded NIAID R01 Grant to Uncover Determinants of Gram-Negative Permeability
Leveraging a Unique Small Molecule Library, VenatoRx seeks to open challenging bottlenecks for antibacterial drug discovery and successfully introduce new antibacterial agents into the clinic
VenatoRx Pharmaceuticals, a world leader in antibacterial and antiviral drug research and development, announced that its Chief Business Officer, Tony Meehan, MBA, PhD, will present at the 2019 BIO CEO & Investor Conference.
VenatoRx Pharmaceuticals is a world leader in antibacterial and antiviral drug research and development. VenatoRx’s lead product, VNRX-5133, is an injectable beta-lactamase inhibitor (BLI) that features uniquely potent and selective activity against both serine- and metallo-beta-lactamases.
VenatoRx Pharmaceuticals to Present in vitro, in vivo and Phase I Data for cefepime/VNRX-5133 at IDWeek 2018
VenatoRx Pharmaceuticals will feature its lead clinical antibacterial candidate, cefepime/VNRX-5133, at IDWeek 2018 which is taking place in San Francisco, CA this week from October 3-7, 2018.
VenatoRx Pharmaceuticals announced that it was named one of the “2018 Best Places to Work” in the Greater Philadelphia area by the Philadelphia Business Journal.
VenatoRx Pharmaceuticals to present at ASM Microbe in the New Agents Discovery Summary Session and Emerging Tech Talks
The company will also present five posters featuring its lead clinical antibacterial candidate, cefepime/VNRX-5133
VenatoRx Pharmaceuticals announced that its President and CEO, Christopher J. Burns, Ph.D., will present at the UBS Global Healthcare Conference on Monday, May 21, 2018 at 8:00am ET in Ballroom V at the Grand Hyatt New York. The presentation will be webcast at www.venatorx.com/UBS2018.
Pipeline Corner Presentation, Mini Oral Sessions and Paper Poster Session to take place April 22-23
VenatoRx Pharmaceuticals to Present its Lead Clinical Antibacterial Candidate, VNRX-5133, at the American Chemical Society National Meeting
President and CEO, Christopher J. Burns, Ph.D., will present at the First-Time Disclosure of Clinical Candidates Oral Symposium on March 21, 2018 at 3:15pm CT